# S0820, Adenoma and Second Primary Prevention Trial

> **NCT01349881** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **SWOG Cancer Research Network** · enrollment: 354 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Eflornithine placebo & sulindac placebo
- **DRUG:** eflornithine & sulindac placebo
- **DRUG:** Eflornithine placebo & sulindac
- **DRUG:** Eflornithine plus sulindac

## Key facts

- **NCT ID:** NCT01349881
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-08-23
- **Primary completion:** 2027-09-15
- **Final completion:** 2032-02-01
- **Target enrollment:** 354 (ACTUAL)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01349881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01349881, "S0820, Adenoma and Second Primary Prevention Trial". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01349881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*